News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017

CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer

Study is first to evaluate use of sereotactic body radiation therapy in low-risk prostate cancer 10 years post-treatment

CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer

October 10, 2017 — Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent had local disease control 10 years after receiving stereotactic body radiation therapy (SBRT) administered with the CyberKnife System, and toxicity was mild. The study titled, “Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten Year Analysis,” was published online in the Sept. 9, 2017 issue of Cureus.

“This is a groundbreaking study — the first to report on the efficacy and toxicity of SBRT in the treatment of low-risk prostate cancer following 10 years of treatment. All patients participating in the study were treated with the CyberKnife System, which delivers extremely precise radiation treatments using unique, real-time image guidance and automatic motion correction. The study outcomes were excellent both in terms ofdisease control and tolerability, and were superior to long-term conventional intensity-modulated radiation therapy, based on results from other studies,” said Alan Katz, M.D., Flushing Radiation Oncology.

Study participants completed their entire treatment in just five daily sessions, compared to conventional radiation therapy which typically takes 30 to 40 sessions. Additional 10-year outcomes showed:

  • The disease free survival (DFS) rate was 93.7 percent, indicating there were no signs or symptoms of the cancer during the evaluation period;
  • The median prostate specific antigen (PSA) value was 0.1 ng/ml. A low PSA value is associated with a reduced risk of cancer recurrence or metastases; and
  • Patient-reported bowel and urinary function scores showed initial declines, which recovered to baseline where they remained throughout the remainder of the study period.

The prostate gland can move unpredictably throughout the course of treatment, making the ability to track, detect and correct for motion critically important. Throughout the course of treatment, the CyberKnife System continually collects images to determine exactly where the tumor is, ensuring that clinicians deliver radiation exactly where they want it. The system detects the tumor motion and automatically adjusts the radiation beam in real time to match the motion of the tumor, giving clinicians confidence to apply smaller treatment margins and enabling higher doses and fewer treatments.

For more information: www.accuray.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Treatment Planning | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...